Burrows Scott L
CIK 1853327
Transactions on file
31
Tickers traded
Recent activity
| Filed | Txn date | Issuer | Roles | Code | Shares | Value | % since Filing | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-10-03 | 2026-10-01 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 229 | $21.4K | -1.3% | open → |
| 2026-10-03 | 2026-10-01 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 3,071 | $285.4K | -0.7% | open → |
| 2026-10-03 | 2026-10-01 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 2,100 | $193.0K | +0.4% | open → |
| 2026-10-03 | 2026-10-01 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 1,500 | $135.4K | +2.3% | open → |
| 2026-10-03 | 2026-10-01 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 600 | $53.4K | +3.7% | open → |
| 2026-10-03 | 2026-10-01 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Exer. | 7,500 | $108.8K | +536.8% | open → |
| 2026-10-03 | 2026-09-30 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 17,500 | $1.57M | +2.7% | open → |
| 2026-10-03 | 2026-09-30 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Exer. | 17,500 | $253.8K | +536.8% | open → |
| 2026-09-04 | 2026-09-02 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 18,232 | $1.63M | +3.3% | open → |
| 2026-09-04 | 2026-09-01 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 200 | $17.8K | +3.7% | open → |
| 2026-09-04 | 2026-09-01 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 2,016 | $177.5K | +4.9% | open → |
| 2026-09-04 | 2026-09-01 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 4,384 | $381.9K | +6.0% | open → |
| 2026-09-04 | 2026-09-01 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 900 | $77.6K | +7.0% | open → |
| 2026-09-04 | 2026-09-01 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Exer. | 7,500 | $108.8K | +536.8% | open → |
| 2026-08-06 | 2026-08-03 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 100 | $9.7K | -4.9% | open → |
| 2026-08-06 | 2026-08-03 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 2,300 | $221.5K | -4.1% | open → |
| 2026-08-06 | 2026-08-03 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 5,100 | $485.6K | -3.0% | open → |
| 2026-08-06 | 2026-08-03 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Exer. | 7,500 | $108.8K | +536.8% | open → |
| 2026-07-05 | 2026-07-01 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 1,725 | $152.4K | +4.5% | open → |
| 2026-07-05 | 2026-07-01 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 5,775 | $505.6K | +5.5% | open → |
| 2026-07-05 | 2026-07-01 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Exer. | 7,500 | $108.8K | +536.8% | open → |
| 2026-06-27 | 2026-06-25 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 10,000 | $871.4K | +6.0% | open → |
| 2026-06-27 | 2026-06-25 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 5,000 | $435.6K | +6.0% | open → |
| 2026-06-27 | 2026-06-25 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Exer. | 15,000 | $217.5K | +536.8% | open → |
| 2026-06-04 | 2026-06-01 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 3,100 | $223.4K | +28.1% | open → |
| 2026-06-04 | 2026-06-01 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 2,599 | $183.9K | +30.5% | open → |
| 2026-06-04 | 2026-06-01 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 1,801 | $125.6K | +32.4% | open → |
| 2026-06-04 | 2026-06-01 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Exer. | 7,500 | $108.8K | +536.8% | open → |
| 2026-05-02 | 2026-05-01 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 12,500 | $892.1K | +29.4% | open → |
| 2026-05-02 | 2026-05-01 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Exer. | 12,500 | $181.3K | +536.8% | open → |
| 2025-09-03 | 2025-09-02 | SYRE Spyre Therapeutics, Inc. | Officer Chief Financial Officer | Sale | 18,428 | $299.6K | +467.8% | open → |
